675 related articles for article (PubMed ID: 29579622)
1. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
2. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
3. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
4. Adoptive T cell therapy: points to consider.
Yee C
Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
8. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
9. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
10. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
11. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
13. Principles of adoptive T cell therapy in cancer.
Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
[TBL] [Abstract][Full Text] [Related]
14. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
15. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Pietzsch J; Novo C; Videira P; Bachmann M
Blood Cancer J; 2018 Aug; 8(9):81. PubMed ID: 30190468
[No Abstract] [Full Text] [Related]
17. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
18. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function.
Salzer B; Schueller CM; Zajc CU; Peters T; Schoeber MA; Kovacic B; Buri MC; Lobner E; Dushek O; Huppa JB; Obinger C; Putz EM; Holter W; Traxlmayr MW; Lehner M
Nat Commun; 2020 Aug; 11(1):4166. PubMed ID: 32820173
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
20. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
Abbott RC; Cross RS; Jenkins MR
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
